Učitavanje...
Therapeutic Targeting of Pancreatic Cancer via EphA2 Dimeric Agonistic Agents
Recently, we reported on potent EphA2 targeting compounds and demonstrated that dimeric versions of such agents can exhibit remarkably increased agonistic activity in cellular assays compared to the monomers. Here we further characterize the activity of dimeric compounds at the structural, biochemic...
Spremljeno u:
| Izdano u: | Pharmaceuticals (Basel) |
|---|---|
| Glavni autori: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
MDPI
2020
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7281375/ https://ncbi.nlm.nih.gov/pubmed/32397624 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph13050090 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|